Developer docs
API playgroundTry for free, no card

Search company profiles

Medinet Co

Full company profile

uuid003drwj

Namestring
Medinet Co
Legal namestring
株式会社メディネット
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Medinet Co, Ltd. (株式会社メディネット, TSE Growth: 2370) is a Japanese regenerative medicine and cell therapy CDMO founded in 1995 and headquartered in Ota-ku, Tokyo. The company operates the Shinagawa Cell Processing Facility (Shinagawa CPF), a GMP/GCTP-compliant manufacturing site near Haneda Airport that holds both a Specified Cell Product Manufacturing License (FA3150001, since May 2015) and a Regenerative Medical Product Manufacturing License (13FZ110003, since January 2020). Its core business is contract manufacturing and development of immune cell therapies — including αβT, NK, γδT, NKT, and dendritic cell-based products — for medical institutions, university hospitals, and pharmaceutical companies across Japan.

Medinet generates revenue through four streams: (1) Specified Cell Product Manufacturing (CMO) — fee-per-treatment contract processing of immune cells for medical institutions under the Act on the Safety of Regenerative Medicine; (2) Regenerative Medicine Product CDMO — process development through commercial manufacturing under the PMD Act for pharma and biotech clients (including Janssen Pharma for α-GalCer/DC); (3) Value Chain Solutions — engineer dispatching, technical training, facility design, and documentation consulting; and (4) in-house regenerative medicine product development, most notably ATL-DC-101, a dendritic cell vaccine for adult T-cell leukemia co-developed with the National Hospital Organization. Pricing for cell processing services is transaction-based (approximately ¥2 million per patient treatment course at the patient-pay level for immune cell therapy, which is not covered by national health insurance). The company also operates the Self Cancer Tissue Depository (自己がん組織バンク), a service to store patient tumor tissue for future dendritic cell vaccine production (new contract acceptance ending September 2026).

Medinet is publicly listed on the Tokyo Stock Exchange Growth Market (formerly Mothers), with FY2025 revenue of ¥810.3 million, R&D spend of ¥452.5 million (55.8% of revenue), and a customer base anchored by Medical Corporation Koshikai, which accounts for 55.1% of total sales. The company has executed multiple new stock acquisition rights rounds (17th–19th, 2020–2023) and has registered capital of ¥5,102 million as of September 2025. The firm carries cumulative losses and has disclosed going concern risk, though management assesses continuity as not in doubt. Co-founder Yoshiji Kimura founded the company in 1995; current Representative Director and President Kanenao Kubushiro was appointed in 2021.

Short descriptiontext

Medinet Co (TSE Growth: 2370) is a Japanese regenerative medicine CDMO operating the GMP/GCTP-compliant Shinagawa Cell Processing Facility to manufacture immune cell therapies (αβT, NK, γδT, NKT, dendritic cells) for medical institutions and pharmaceutical companies, with in-house development of the ATL-DC-101 cancer vaccine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKahoku, Japan
HQ citystring
Kahoku
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell processing services, regenerative medicine CDMO, immune cell therapy, contract cell manufacturing, cell therapy development
Industry3 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Manufacturing Services (Regenerative Medicine CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Cell processing services (特定細胞加工物製造業)
TypeTransaction Fee
Description

Contract manufacturing of specified cell products for medical institutions under the Regenerative Medicine Safety Act. Revenue is based on cell processing type and number of treatments using a variable fee structure. Cells processed include αβT cells, NK cells, NKT cells, γδT cells, dendritic cells, and others.

medinet-inc.co.jp
2CDMO services (再生医療等製品製造業)
TypeTransaction Fee
Description

Contract development and manufacturing of regenerative medicine products and investigational products for pharmaceutical companies and biotech firms, under the Pharmaceutical and Medical Device Act. Covers process development through commercial production.

medinet-inc.co.jp
3Value chain solutions (バリューチェーン事業)
TypeProfessional Services
Description

Engineer dispatching, technical training, facility design and management consulting, and documentation support for cell processing operations.

medinet-inc.co.jp
4Regenerative medicine product development
TypeLicensing Royalties
Description

In-house development of regenerative medicine products (regenerative medical products) targeting manufacturing and marketing approval, including ATL-DC-101 (dendritic cell vaccine for adult T-cell leukemia).

medinet-inc.co.jp
5Self Cancer Tissue Depository (自己がん組織バンク)
TypeManaged Services
Description

Free tissue storage service for patients; tissue used for dendritic cell vaccine production. Tissue storage is free; transport costs borne by contracting party.

medinet-inc.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Immune cell therapy treatment course cost is approximately 2 million yen per course (patient-facing, not insured)
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Immunocyte therapy is an advanced medical technology not covered by national health insurance. Per course treatment cost is approximately 2 million yen. The company receives processing fees from contracted medical institutions based on cell type and number of treatments.

medinet-inc.co.jp
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1自己がん組織バンク (Self Cancer Cell Depository)
Description

Japan's first treatment-focused cancer tissue storage service for future cancer treatment using the patient's own cancer tissue for dendritic cell vaccines.

medinet-inc.co.jp
Core offering1 text field

Medinet Co is a publicly-traded Japanese regenerative medicine and cell therapy CDMO providing contract cell processing services to medical institutions and pharmaceutical companies under Japan's Act on the Safety of Regenerative Medicine and the Pharmaceutical and Medical Device Act. Its offerings span Specific Cell Products Manufacturing (CMO), CDMO Business (process development through commercial production of regenerative medicine products), Value Chain Business (technical personnel dispatch, facility design, consulting, documentation), and the Self Cancer Tissue Bank service. Cell processing covers αβT, NK, γδT, NKT, and dendritic cell therapies, supported by the GMP/GCTP-compliant Shinagawa CPF manufacturing facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 200,000 cell processing instances delivered to medical institutions with zero major incidents
+2 more records
Product overview1 text field

Medinet Co is a Contract Development and Manufacturing Organization (CDMO) providing a ONE-STOP total solution for regenerative medicine and cell therapy. The company operates through four main business segments: (1) Specific Cell Products Manufacturing - contract manufacturing of specified cell products for medical institutions; (2) CDMO Business - development and manufacturing services for regenerative medical products and investigational products; (3) Value Chain Business - comprehensive solutions including personnel dispatch, facility design, and consulting; and (4) Self Cancer Tissue Bank - cancer tissue storage service. The company offers multiple immune cell therapy technologies including αβT cells, NK cells, γδT cells, dendritic cells, and NKT cell-activated dendritic cells. All operations are supported by the Shinagawa Cell Processing Facility (品川CPF), a GMP/GCTP-compliant manufacturing facility.

Product and service4 records
1Specific Cell Products Manufacturing (特定細胞加工物製造業)
CategoryContract Cell Processing Services (CMO)
Description

Contract manufacturing of specified cell products (αβT, NK, γδT, NKT, and dendritic cell therapies) for medical institutions under Japan's Act on the Safety of Regenerative Medicine. Includes cell isolation, culture, expansion to clinical-scale cell numbers, and delivery to medical institutions.

2CDMO Business (再生医療等製品/治験製品のCDMO事業)
CategoryRegenerative Medicine Contract Development and Manufacturing (CDMO)
Description

Contract development and manufacturing services for regenerative medical products and investigational products, from process development through commercial manufacturing under Japan's Pharmaceutical and Medical Device Act (PMD Act). Targeted at pharmaceutical companies and biotech firms developing regenerative medicine products.

3Value Chain Business (バリューチェーン事業)
CategoryConsulting and Technical Services
Description

Total solution services for the regenerative medicine cell processing value chain, including technical personnel dispatching, technical training, facility design and management consulting, and documentation support for cell processing operations.

4Self Cancer Tissue Bank (自己がん組織バンク)
CategoryCancer Tissue Banking Service
Description

Service to collect, process, and store a patient's own cancer tissue excised during surgery for future use in dendritic cell vaccine manufacturing. Tissue storage is free; transport costs are borne by the contracting party.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-01
Description

Joint development collaboration on electroporation technology for dendritic cell vaccine manufacturing. MaxCyte's electroporation platform (Cell Loading System) is used in Medinet's DC vaccine processing.

2Kyoto Prefectural University of Medicine (京都府公立大学法人京都府立医科大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Joint research agreement and joint patent application for cell therapy technologies. Combines academic research capabilities with Medinet's development and manufacturing expertise.

medinet-inc.co.jp
3Kyushu University (国立大学法人九州大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Joint research agreement for regenerative medicine and cell therapy. Long-standing relationship including joint research department 'Advanced Cell Therapy Research Department' established at Kyushu University Center for Advanced Medical Innovation in 2012.

medinet-inc.co.jp
4Medigen Biotechnology Corp. (Taiwan)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-10-01
Description

Licensing agreement for γδT cell culture processing technology to Taiwanese listed biopharmaceutical company. Enables international expansion of Medinet's immune cell therapy technologies.

medinet-inc.co.jp
5National Cancer Center (国立研究開発法人国立がん研究センター)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

Joint research agreement for regenerative medicine and cell therapy development. Combines National Cancer Center's research capabilities with Medinet's cell processing expertise.

medinet-inc.co.jp
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-06-01
Description

Cell processing facility management support services for university hospital's cell therapy programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

Contract development agreement for manufacturing technology of regenerative medicine products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-03-01
Description

Joint development agreement with National Hospital Organization aiming to obtain manufacturing/marketing approval for ATL-DC-101, a dendritic cell vaccine for adult T-cell leukemia, as a regenerative medicine product.

9Kenkoigaku Association (一般財団法人健康医学協会)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-05-01
Description

Agreement for specified cell product manufacturing services.

medinet-inc.co.jp
Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Japanese pharmaceutical company (TYO: 4552) with established cell therapy products (e.g., TEMCELL HS-Injection) and broader regenerative medicine capabilities. JCR is a more diversified pharmaceutical company but overlaps with Medinet in contract cell processing, regenerative medicine manufacturing, and serving Japanese medical institutions.

TypeBroad incumbent
Description

Global CDMO leader (SWX: LONN) with significant cell and gene therapy manufacturing capabilities including autologous and allogeneic cell therapy services. Lonza is a benchmark for global cell therapy CDMO scale and increasingly serves Japanese cell therapy developers, putting it in competitive overlap with Medinet for international CDMO contracts.

TypeBroad incumbent
Description

Global CDMO (NYSE: CTLT) with cell therapy manufacturing capabilities and a broad development services portfolio. Catalent is comparable to Medinet in providing specialized cell therapy manufacturing services to pharmaceutical and biotech clients, particularly for investigational and commercial product manufacturing.

TypeBroad incumbent
Description

Japanese pharmaceutical company (TYO: 4503) that has made significant investments in cell therapy through acquisitions (Universal Cells) and internal programs. Astellas represents a potential customer and competitor in cell therapy development and could leverage its scale to capture value currently served by Medinet's CDMO.

TypeBroad incumbent
Description

Global biopharmaceutical CDMO and subsidiary of FUJIFILM Holdings with growing cell and gene therapy manufacturing capacity. FUJIFILM Diosynth is a domestic Japanese-headquartered competitor with greater scale and capital, targeting the same pharma/biotech customers seeking cell therapy manufacturing services in Asia.

6Takara Bio Inc.
TypeDirect peer
Description

Japanese cell and gene therapy CDMO/biotech (TYO: 4974) offering cell processing, viral vector manufacturing, and regenerative medicine services. Takara Bio is a direct competitor in cell therapy manufacturing infrastructure and serves overlapping pharma/biotech customers in Japan and internationally.

TypeBroad incumbent
Description

Japan's largest CRO/CDMO group (TYO: 2309) providing drug development services from preclinical through manufacturing. While broader in scope than Medinet, CMIC represents the established alternative for Japanese pharma/biotech seeking development and manufacturing partners and competes for some of the same institutional clients.

TypeBroad incumbent
Description

Chinese-headquartered global CDMO (HKEX: 2269) with growing cell and gene therapy manufacturing capabilities. WuXi is a competitor for global cell therapy manufacturing contracts and increasingly serves Japanese biotech developers, creating indirect competitive pressure on Medinet's CDMO positioning.

TypeDirect peer
Description

Japanese regenerative medicine company (TYO: 4593) developing stem cell therapies and operating in the same cell therapy and regenerative medicine ecosystem. Both companies are TSE Growth-listed and compete for the same pool of Japanese patients, medical institutions, and research collaborations in cell-based therapies.

TypeBroad incumbent
Description

Korean-headquartered global CDMO (KRX: 207940) expanding into cell and gene therapy manufacturing. Samsung Biologics competes for the same international cell therapy manufacturing contracts and is establishing Asia-Pacific CDMO presence, putting it in broader competitive overlap with Medinet for Japanese and Asian pharma clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medinet Co

Cell Therapy Manufacturing Services (Regenerative Medicine CDMO)medinet-inc.co.jp

Medinet Co (TSE Growth: 2370) is a Japanese regenerative medicine CDMO operating the GMP/GCTP-compliant Shinagawa Cell Processing Facility to manufacture immune cell therapies (αβT, NK, γδT, NKT, dendritic cells) for medical institutions and pharmaceutical companies, with in-house development of the ATL-DC-101 cancer vaccine.

What Medinet Co does

Medinet Co, Ltd. (株式会社メディネット, TSE Growth: 2370) is a Japanese regenerative medicine and cell therapy CDMO founded in 1995 and headquartered in Ota-ku, Tokyo. The company operates the Shinagawa Cell Processing Facility (Shinagawa CPF), a GMP/GCTP-compliant manufacturing site near Haneda Airport that holds both a Specified Cell Product Manufacturing License (FA3150001, since May 2015) and a Regenerative Medical Product Manufacturing License (13FZ110003, since January 2020). Its core business is contract manufacturing and development of immune cell therapies — including αβT, NK, γδT, NKT, and dendritic cell-based products — for medical institutions, university hospitals, and pharmaceutical companies across Japan.

Medinet generates revenue through four streams: (1) Specified Cell Product Manufacturing (CMO) — fee-per-treatment contract processing of immune cells for medical institutions under the Act on the Safety of Regenerative Medicine; (2) Regenerative Medicine Product CDMO — process development through commercial manufacturing under the PMD Act for pharma and biotech clients (including Janssen Pharma for α-GalCer/DC); (3) Value Chain Solutions — engineer dispatching, technical training, facility design, and documentation consulting; and (4) in-house regenerative medicine product development, most notably ATL-DC-101, a dendritic cell vaccine for adult T-cell leukemia co-developed with the National Hospital Organization. Pricing for cell processing services is transaction-based (approximately ¥2 million per patient treatment course at the patient-pay level for immune cell therapy, which is not covered by national health insurance). The company also operates the Self Cancer Tissue Depository (自己がん組織バンク), a service to store patient tumor tissue for future dendritic cell vaccine production (new contract acceptance ending September 2026).

Medinet is publicly listed on the Tokyo Stock Exchange Growth Market (formerly Mothers), with FY2025 revenue of ¥810.3 million, R&D spend of ¥452.5 million (55.8% of revenue), and a customer base anchored by Medical Corporation Koshikai, which accounts for 55.1% of total sales. The company has executed multiple new stock acquisition rights rounds (17th–19th, 2020–2023) and has registered capital of ¥5,102 million as of September 2025. The firm carries cumulative losses and has disclosed going concern risk, though management assesses continuity as not in doubt. Co-founder Yoshiji Kimura founded the company in 1995; current Representative Director and President Kanenao Kubushiro was appointed in 2021.

Medinet Co firmographics

Firmographics
Name
Medinet Co
Legal name
株式会社メディネット
Website
https://medinet-inc.co.jp
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
1–10 employees
Short description
Medinet Co (TSE Growth: 2370) is a Japanese regenerative medicine CDMO operating the GMP/GCTP-compliant Shinagawa Cell Processing Facility to manufacture immune cell therapies (αβT, NK, γδT, NKT, dendritic cells) for medical institutions and pharmaceutical companies, with in-house development of the ATL-DC-101 cancer vaccine.
Ownership category
akta.pro rank

Medinet Co industry classification

Industry
Product category
Cell Therapy Manufacturing Services (Regenerative Medicine CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell processing services
  • Regenerative medicine CDMO
  • Immune cell therapy
  • Contract cell manufacturing
  • Cell therapy development

Where Medinet Co is headquartered

Location

Headquarters

HQ city
Kahoku
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Medinet Co business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Cell processing services (特定細胞加工物製造業): Contract manufacturing of specified cell products for medical institutions under the Regenerative Medicine Safety Act. Revenue is based on cell processing type and number of treatments using a variable fee structure. Cells processed include αβT cells, NK cells, NKT cells, γδT cells, dendritic cells, and others.
  2. CDMO services (再生医療等製品製造業): Contract development and manufacturing of regenerative medicine products and investigational products for pharmaceutical companies and biotech firms, under the Pharmaceutical and Medical Device Act. Covers process development through commercial production.
  3. Value chain solutions (バリューチェーン事業): Engineer dispatching, technical training, facility design and management consulting, and documentation support for cell processing operations.
  4. Regenerative medicine product development: In-house development of regenerative medicine products (regenerative medical products) targeting manufacturing and marketing approval, including ATL-DC-101 (dendritic cell vaccine for adult T-cell leukemia).
  5. Self Cancer Tissue Depository (自己がん組織バンク): Free tissue storage service for patients; tissue used for dendritic cell vaccine production. Tissue storage is free; transport costs borne by contracting party.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goImmune cell therapy treatment course cost is approximately 2 million yen per course (patient-facing, not insured)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Medinet Co product offering

Product offering

Core offering

Medinet Co is a publicly-traded Japanese regenerative medicine and cell therapy CDMO providing contract cell processing services to medical institutions and pharmaceutical companies under Japan's Act on the Safety of Regenerative Medicine and the Pharmaceutical and Medical Device Act. Its offerings span Specific Cell Products Manufacturing (CMO), CDMO Business (process development through commercial production of regenerative medicine products), Value Chain Business (technical personnel dispatch, facility design, consulting, documentation), and the Self Cancer Tissue Bank service. Cell processing covers αβT, NK, γδT, NKT, and dendritic cell therapies, supported by the GMP/GCTP-compliant Shinagawa CPF manufacturing facility.

Product overview

Medinet Co is a Contract Development and Manufacturing Organization (CDMO) providing a ONE-STOP total solution for regenerative medicine and cell therapy. The company operates through four main business segments: (1) Specific Cell Products Manufacturing - contract manufacturing of specified cell products for medical institutions; (2) CDMO Business - development and manufacturing services for regenerative medical products and investigational products; (3) Value Chain Business - comprehensive solutions including personnel dispatch, facility design, and consulting; and (4) Self Cancer Tissue Bank - cancer tissue storage service. The company offers multiple immune cell therapy technologies including αβT cells, NK cells, γδT cells, dendritic cells, and NKT cell-activated dendritic cells. All operations are supported by the Shinagawa Cell Processing Facility (品川CPF), a GMP/GCTP-compliant manufacturing facility.

Differentiator

Problem solved

Functional benefit

Brands

  • 自己がん組織バンク (Self Cancer Cell Depository): Japan's first treatment-focused cancer tissue storage service for future cancer treatment using the patient's own cancer tissue for dendritic cell vaccines.

Products and services

  • Specific Cell Products Manufacturing (特定細胞加工物製造業) Contract manufacturing of specified cell products (αβT, NK, γδT, NKT, and dendritic cell therapies) for medical institutions under Japan's Act on the Safety of Regenerative Medicine. Includes cell isolation, culture, expansion to clinical-scale cell numbers, and delivery to medical institutions.
  • CDMO Business (再生医療等製品/治験製品のCDMO事業) Contract development and manufacturing services for regenerative medical products and investigational products, from process development through commercial manufacturing under Japan's Pharmaceutical and Medical Device Act (PMD Act). Targeted at pharmaceutical companies and biotech firms developing regenerative medicine products.
  • Value Chain Business (バリューチェーン事業) Total solution services for the regenerative medicine cell processing value chain, including technical personnel dispatching, technical training, facility design and management consulting, and documentation support for cell processing operations.
  • Self Cancer Tissue Bank (自己がん組織バンク) Service to collect, process, and store a patient's own cancer tissue excised during surgery for future use in dendritic cell vaccine manufacturing. Tissue storage is free; transport costs are borne by the contracting party.

Quantifiable outcome

  • Over 200,000 cell processing instances delivered to medical institutions with zero major incidents
  • +2 more outcomes

Companies that use Medinet Co

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Medinet Co technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Medinet Co partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • MaxCyte Inc. (US)coreTechnology or Integration · 1 February 2023Joint development collaboration on electroporation technology for dendritic cell vaccine manufacturing. MaxCyte's electroporation platform (Cell Loading System) is used in Medinet's DC vaccine processing.
  • Kyoto Prefectural University of Medicine (京都府公立大学法人京都府立医科大学)coreStrategic or Co-development Partner · 1 November 2019Joint research agreement and joint patent application for cell therapy technologies. Combines academic research capabilities with Medinet's development and manufacturing expertise.
  • Kyushu University (国立大学法人九州大学)coreStrategic or Co-development Partner · 1 November 2019Joint research agreement for regenerative medicine and cell therapy. Long-standing relationship including joint research department 'Advanced Cell Therapy Research Department' established at Kyushu University Center for Advanced Medical Innovation in 2012.
  • Medigen Biotechnology Corp. (Taiwan)coreTechnology or Integration · 1 October 2019Licensing agreement for γδT cell culture processing technology to Taiwanese listed biopharmaceutical company. Enables international expansion of Medinet's immune cell therapy technologies.
  • National Cancer Center (国立研究開発法人国立がん研究センター)coreStrategic or Co-development Partner · 1 October 2019Joint research agreement for regenerative medicine and cell therapy development. Combines National Cancer Center's research capabilities with Medinet's cell processing expertise.
  • Kanazawa University (国立大学法人金沢大学)minorStrategic or Co-development Partner · 1 June 2019Cell processing facility management support services for university hospital's cell therapy programs.
  • JUNTEN BIO Co., Ltd. (株式会社JUNTEN BIO)minorStrategic or Co-development Partner · 1 December 2018Contract development agreement for manufacturing technology of regenerative medicine products.
  • National Hospital OrganizationcoreStrategic or Co-development Partner · 1 March 2018Joint development agreement with National Hospital Organization aiming to obtain manufacturing/marketing approval for ATL-DC-101, a dendritic cell vaccine for adult T-cell leukemia, as a regenerative medicine product.
  • Kenkoigaku Association (一般財団法人健康医学協会)minorStrategic or Co-development Partner · 1 May 2017Agreement for specified cell product manufacturing services.

Scale indicators9 records

Recent moves14 records

Expansion highlights6 records

Medinet Co competitors and assessment

Company assessment

Broad incumbents

  • JCR Pharmaceuticals Co., Ltd. Japanese pharmaceutical company (TYO: 4552) with established cell therapy products (e.g., TEMCELL HS-Injection) and broader regenerative medicine capabilities. JCR is a more diversified pharmaceutical company but overlaps with Medinet in contract cell processing, regenerative medicine manufacturing, and serving Japanese medical institutions.
  • Lonza Group AG: Global CDMO leader (SWX: LONN) with significant cell and gene therapy manufacturing capabilities including autologous and allogeneic cell therapy services. Lonza is a benchmark for global cell therapy CDMO scale and increasingly serves Japanese cell therapy developers, putting it in competitive overlap with Medinet for international CDMO contracts.
  • Catalent, Inc. Global CDMO (NYSE: CTLT) with cell therapy manufacturing capabilities and a broad development services portfolio. Catalent is comparable to Medinet in providing specialized cell therapy manufacturing services to pharmaceutical and biotech clients, particularly for investigational and commercial product manufacturing.
  • Astellas Pharma Inc. Japanese pharmaceutical company (TYO: 4503) that has made significant investments in cell therapy through acquisitions (Universal Cells) and internal programs. Astellas represents a potential customer and competitor in cell therapy development and could leverage its scale to capture value currently served by Medinet's CDMO.
  • FUJIFILM Diosynth Biotechnologies: Global biopharmaceutical CDMO and subsidiary of FUJIFILM Holdings with growing cell and gene therapy manufacturing capacity. FUJIFILM Diosynth is a domestic Japanese-headquartered competitor with greater scale and capital, targeting the same pharma/biotech customers seeking cell therapy manufacturing services in Asia.
  • CMIC Holdings Co., Ltd. Japan's largest CRO/CDMO group (TYO: 2309) providing drug development services from preclinical through manufacturing. While broader in scope than Medinet, CMIC represents the established alternative for Japanese pharma/biotech seeking development and manufacturing partners and competes for some of the same institutional clients.
  • WuXi Biologics (WuXi AppTec): Chinese-headquartered global CDMO (HKEX: 2269) with growing cell and gene therapy manufacturing capabilities. WuXi is a competitor for global cell therapy manufacturing contracts and increasingly serves Japanese biotech developers, creating indirect competitive pressure on Medinet's CDMO positioning.
  • Samsung Biologics Co., Ltd. Korean-headquartered global CDMO (KRX: 207940) expanding into cell and gene therapy manufacturing. Samsung Biologics competes for the same international cell therapy manufacturing contracts and is establishing Asia-Pacific CDMO presence, putting it in broader competitive overlap with Medinet for Japanese and Asian pharma clients.

Direct peers

  • Takara Bio Inc. Japanese cell and gene therapy CDMO/biotech (TYO: 4974) offering cell processing, viral vector manufacturing, and regenerative medicine services. Takara Bio is a direct competitor in cell therapy manufacturing infrastructure and serves overlapping pharma/biotech customers in Japan and internationally.
  • Healios K.K. Japanese regenerative medicine company (TYO: 4593) developing stem cell therapies and operating in the same cell therapy and regenerative medicine ecosystem. Both companies are TSE Growth-listed and compete for the same pool of Japanese patients, medical institutions, and research collaborations in cell-based therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Medinet Co social profiles

Digital presence

Medinet Co compliance and trust

Trust signal

Compliance3 records

Medinet Co financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medinet Co leadership team

Management profile

Number of profiles

Profiles10 records

Medinet Co subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Medinet Co funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medinet Co M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medinet Co

What does Medinet Co do?

Medinet Co is a publicly-traded Japanese regenerative medicine and cell therapy CDMO providing contract cell processing services to medical institutions and pharmaceutical companies under Japan's Act on the Safety of Regenerative Medicine and the Pharmaceutical and Medical Device Act. Its offerings span Specific Cell Products Manufacturing (CMO), CDMO Business (process development through commercial production of regenerative medicine products), Value Chain Business (technical personnel dispatch, facility design, consulting, documentation), and the Self Cancer Tissue Bank service. Cell processing covers αβT, NK, γδT, NKT, and dendritic cell therapies, supported by the GMP/GCTP-compliant Shinagawa CPF manufacturing facility.

Is Medinet Co a public or private company?

Medinet Co is a public company. It is classified as public and is currently operating.

When was Medinet Co founded?

Medinet Co was founded in 1995. It employs 1 to 10 people.

Where is Medinet Co based?

Medinet Co is headquartered in Kahoku, Japan, in the Asia region.

How does Medinet Co make money?

Five revenue lines are on record. Cell processing services (特定細胞加工物製造業) is the primary driver. The others are CDMO services (再生医療等製品製造業), value chain solutions (バリューチェーン事業), regenerative medicine product development and self Cancer Tissue Depository (自己がん組織バンク).

Who are Medinet Co's main competitors?

Broad incumbents on record are JCR Pharmaceuticals Co., Ltd., Lonza Group AG, Catalent, Inc., Astellas Pharma Inc., FUJIFILM Diosynth Biotechnologies, CMIC Holdings Co., Ltd., WuXi Biologics (WuXi AppTec) and Samsung Biologics Co., Ltd.. Direct peers are Takara Bio Inc. and Healios K.K..

Does Medinet Co have an API?

No public API is recorded for Medinet Co.

What industry is Medinet Co in?

Medinet Co's product category is Cell Therapy Manufacturing Services (Regenerative Medicine CDMO). Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals